CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions.

Cohen-Solal JF., Pohl CS., Cummings SM., Gygi JP., Safikhani Z., Bartocha B., Buckley CD., Dong Y., Eyerich K., Karsen SD., Lynch GR., Macoritto M., Morisset PA., Nelson OD., Radstake T., Rieder F., Rivas J., Savaryn JP., Smith KM., Stulir M., Szynal C., Tylek C., Veldman GM., Wasserman LG., Westmoreland S., Chaudhary N., Staron MM.

DOI

10.1186/s10020-026-01462-z

Type

Journal article

Publication Date

2026-03-28T00:00:00+00:00

Keywords

CD64, Crohn’s disease, Fc portion, FcγRI, Guselkumab, Inflammatory bowel disease, Psoriasis, Risankizumab, Ulcerative colitis, Ustekinumab

Permalink More information Close